5 unchanged sentences
Rule 10b5-1 under the Exchange Act provides an affirmative defense that enables directors and officers to prearrange transactions in our securities in a manner that avoids concerns about initiating transactions while in possession of material nonpublic information.
−Removed: None of our directors or officers terminated a Rule 10b5-1 trading arrangement or adopted or terminated a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during the quarterly period covered by this report.
+Added: Each Rule 10b5-1 trading arrangement described below was entered into in accordance with the Company’s insider trading policy, and only permitted or permits transactions upon the expiration of the applicable mandatory cooling-off periods under Rule 10b5-1 of the Exchange Act.
+Added: Actual transactions are required to be disclosed publicly in Section 16 filings with the SEC.
+Added: The following table describes, for the quarterly period covered by this report, each trading arrangement for the sale or purchase of Company securities adopted or terminated by our directors and officers that is either (1) a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) (a “Rule 10b5-1 trading arrangement”) or (2) a “non-Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K):
+Added: Action Taken (Date of Action)
+Added: Type of Trading Arrangement
+Added: Nature of Trading Arrangement
+Added: Duration of Trading Arrangement
+Added: Aggregate Number of Securities
+Added: Rahul Ballal ( Director )
+Added: Adoption ( August 3, 2024 )
+Added: Rule 10b5-1 trading arrangement
+Added: Through and including October 31, 2025
+Added: Up to 20,000 shares
+Added: James Burns ( Chief Legal Officer )
+Added: Adoption ( August 5, 2024 )
+Added: Rule 10b5-1 trading arrangement
+Added: Through and including December 31, 2024
+Added: Up to 21,752 shares
+Added: David Scadden ( Director )
+Added: Adoption ( September 6, 2024 )
+Added: Rule 10b5-1 trading arrangement
+Added: Through and including December 10, 2025
+Added: Up to 2,400 shares
Incorporated by Reference
4 unchanged sentences
8-K 001-36014 March 3, 2023 3.1
−Removed: 10.1† Purchase and Sale Agreement, dated May 24, 2024, by and between the Registrant and Royalty Pharma Investments 2019 ICAV
31.1 Certification of principal executive officer pursuant to Rule 13a 14(a)/15d 14(a) of the Securities Exchange Act of 1934, as amended.
4 unchanged sentences
§1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
−Removed: XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are not embedded within the Inline XBRL document X
−Removed: XBRL Taxonomy Extension Schema Document X
−Removed: XBRL Taxonomy Calculation Linkbase Document X
−Removed: XBRL Taxonomy Extension Definition Linkbase Document X
−Removed: XBRL Taxonomy Label Linkbase Document X
−Removed: XBRL Taxonomy Presentation Linkbase Document X
+Added: 101.INS XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are not embedded within the Inline XBRL document X
+Added: 101.SCH XBRL Taxonomy Extension Schema Document X
+Added: 101.CAL XBRL Taxonomy Calculation Linkbase Document X
+Added: 101.DEF XBRL Taxonomy Extension Definition Linkbase Document X
+Added: 101.LAB XBRL Taxonomy Label Linkbase Document X
+Added: 101.PRE XBRL Taxonomy Presentation Linkbase Document X
104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101.INS) X
1 unchanged sentence
Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent specifically incorporated by reference into such filing.
−Removed: † Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
AGIOS PHARMACEUTICALS, INC.
−Removed: August 1, 2024 By:
+Added: October 31, 2024 By:
/s/ Brian Goff
1 unchanged sentence
(principal executive officer)
−Removed: August 1, 2024 By:
+Added: October 31, 2024 By:
/s/ Cecilia Jones
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.